Neurochemical and behavioral responses to inflammatory immune stressors

Frontiers in Bioscience - Scholar

Volumn 1 S, Issue 1, 2009, Pages 275-295

  Gibb, Julie ^a   Audet, Marie Claude ^a   Hayley, Shawn ^a   Anisman, Hymie ^a  

^a CARLETON UNIVERSITY   (Canada)

Author keywords

Cytokines; Depression; Immunotherapy; Neurotransmission; Review; Sickness behavior; Stress

Indexed keywords

CYTOKINE;

ANIMAL; ANIMAL BEHAVIOR; DEPRESSION; HUMAN; IMMUNOLOGY; INFLAMMATION; MENTAL DISEASE; PHYSIOLOGY; REVIEW;

ANIMALS; BEHAVIOR, ANIMAL; CYTOKINES; DEPRESSION; HUMANS; INFLAMMATION; MENTAL DISORDERS;

EID: 77954526454     PISSN: 19450516     EISSN: 19450524     Source Type: Journal    
DOI: 10.2741/e26     Document Type: Article

References (230)

1. Anisman H., Z. Merali, S. Hayley: Neurotransmitter, peptide and cytokine processes in relation to depressive disorder: comorbidity between depression and neurodegenerative disorders. Prog Neurobiol 85, 1-74 (2008)
2. Duman R. S., L. M. Monteggia: A neurotrophic model for stress-related mood disorders. Biol Psychiatry 59, 1116-1127 (2006)
3. Anisman H., K. Matheson: Stress, depression, and anhedonia: caveats concerning animal models. Neurosci Biobehav Rev 29, 525-546 (2005) (Pubitemid 40755455)
4. Maes M.: Evidence for an immune response in major depression: a review and hypothesis. Prog Neuropsychopharmacol Biol Psychiatry 19, 11-38 (1995)
5. Maes M.: Major depression and activation of the inflammatory response system. Adv Exp Med Biol 461, 25-46 (1999)
6. Dantzer R., J. C. O'Connor, G. G. Freund, R. W. Johnson, K. W. Kelley: From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 9, 46-56 (2008) (Pubitemid 350295688)
7. Hayley S., H. Anisman: Multiple mechanisms of cytokine action in neurodegenerative and psychiatric states: neurochemical and molecular substrates. Curr Pharm Des 11, 947-962 (2005) (Pubitemid 40331297)
8. Yirmiya R.: Depression in medical illness: the role of the immune system. West J Med 173, 333-336 (2000)
9. Raison C. L., L. Capuron, A. H. Miller: Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol 27, 24-31 (2006) (Pubitemid 43083561)
10. Herman J. P., W. E. Cullinan: Neurocircuitry of stress: central control of the hypothalamo-pituitary-adrenocortical axis. Trends Neurosci 20, 78-84 (1997) (Pubitemid 27050702)
11. Alkharfy K. M., J. A. Kellum, G. R. Matzke: Unintended immunomodulation: part I. Effects of common clinical conditions on cytokine biosynthesis. Shock 13, 333-345 (2000)
12. Oberholzer A., S. M. Souza, S. K. Tschoeke, C. Oberholzer, A. Abouhamze, J. P. Pribble, L. L. Moldawer: Plasma cytokine measurements augment prognostic scores as indicators of outcome in patients with severe sepsis. Shock 23, 488-493 (2005) (Pubitemid 40677419)
13. Banks W. A., S. Dohgu, J. L. Lynch, M. A. Fleegal-DeMotta, M. A. Erickson, R. Nakaoke, T. Q. Vo: Nitric oxide isoenzymes regulate lipopolysaccharide-enhanced insulin transport across the blood-brain barrier. Endocrinology 149, 1514-1523 (2008) (Pubitemid 351468333)
14. Banks W. A., A. J. Kastin: Blood to brain transport of interleukin links the immune and central nervous systems. Life Sci 48, PL117-121 (1991)
15. Saija A., P. Princi, M. Lanza, M. Scalese, E. Aramnejad, A. De Sarro: Systemic cytokine administration can affect blood-brain barrier permeability in the rat. Life Sci 56, 775-784 (1995)
16. de Vries H. E., M. C. Blom-Roosemalen, M. van Oosten, A. G. de Boer, T. J. van Berkel, D. D. Breimer, J. Kuiper: The influence of cytokines on the integrity of the bloodbrain barrier in vitro. J Neuroimmunol 64, 37-43 (1996) (Pubitemid 26052072)
17. Rivest S., S. Lacroix, L. Vallieres, S. Nadeau, J. Zhang, N. Laflamme: How the blood talks to the brain parenchyma and the paraventricular nucleus of the hypothalamus during systemic inflammatory and infectious stimuli. Proc Soc Exp Biol Med 223, 22-38 (2000) (Pubitemid 30182654)
18. Konsman J. P., P. Parnet, R. Dantzer: Cytokine-induced sickness behaviour: mechanisms and implications. Trends Neurosci 25, 154-159 (2002) (Pubitemid 34164341)
19. Nadeau S., S. Rivest: Effects of circulating tumor necrosis factor on the neuronal activity and expression of the genes encoding the tumor necrosis factor receptors (p55 and p75) in the rat brain: a view from the blood-brain barrier. Neuroscience 93, 1449-1464 (1999) (Pubitemid 29397574)
20. Johnson A. B., S. Bake, D. K. Lewis, F. Sohrabji: Temporal expression of IL-1beta protein and mRNA in the brain after systemic LPS injection is affected by age and estrogen. J Neuroimmunol 174, 82-91 (2006)
21. Kamm K., W. Vanderkolk, C. Lawrence, M. Jonker, A. T. Davis: The effect of traumatic brain injury upon the concentration and expression of interleukin-1beta and interleukin-10 in the rat. J Trauma 60, 152-157 (2006)
22. Zhu Y., K. Saito, Y. Murakami, M. Asano, Y. Iwakura, M. Seishima: Early increase in mRNA levels of pro-inflammatory cytokines and their interactions in the mouse hippocampus after transient global ischemia. Neurosci Lett 393, 122-126 (2006) (Pubitemid 41821092)
23. Churchill L., P. Taishi, M. Wang, J. Brandt, C. Cearley, A. Rehman, J. M. Krueger: Brain distribution of cytokine mRNA induced by systemic administration of interleukin-1beta or tumor necrosis factor alpha. Brain Res 1120, 64-73 (2006) (Pubitemid 44648017)
24. Ledeboer A., R. Binnekade, J. J. Breve, J. G. Bol, F. J. Tilders, A. M. Van Dam: Site-specific modulation of LPS-induced fever and interleukin-1 beta expression in rats by interleukin-10. Am J Physiol Regul Integr Comp Physiol 282, R1762-1772 (2002) (Pubitemid 34664502)
25. Rivest S.: How circulating cytokines trigger the neural circuits that control the hypothalamic-pituitaryadrenal axis. Psychoneuroendocrinology 26, 761-788 (2001) (Pubitemid 32918282)
26. Sriram K., J. M. Matheson, S. A. Benkovic, D. B. Miller, M. I. Luster, J. P. O'Callaghan: Deficiency of TNF receptors suppresses microglial activation and alters the susceptibility of brain regions to MPTP-induced neurotoxicity: role of TNF-alpha. FASEB J 20, 670-682 (2006) (Pubitemid 44933311)
27. Maier S. F., K. T. Nguyen, T. Deak, E. D. Milligan, L. R. Watkins: Stress, learned helplessness, and brain interleukin-1 beta. Adv Exp Med Biol 461, 235-249 (1999)
28. Miyahara S., T. Komori, R. Fujiwara, K. Shizuya, M. Yamamoto, M. Ohmori, Y. Okazaki: Effects of repeated stress on expression of interleukin-6 (IL-6) and IL-6 receptor mRNAs in rat hypothalamus and midbrain. Life Sci 66, PL93-98 (2000) (Pubitemid 30062929)
29. Nguyen K. T., T. Deak, S. M. Owens, T. Kohno, M. Fleshner, L. R. Watkins, S. F. Maier: Exposure to acute stress induces brain interleukin-1beta protein in the rat. J Neurosci 18, 2239-2246 (1998) (Pubitemid 28141428)
30. Brebner K., S. Hayley, R. Zacharko, Z. Merali, H. Anisman: Synergistic effects of interleukin-1beta, interleukin-6, and tumor necrosis factor-alpha: central monoamine, corticosterone, and behavioral variations. Neuropsychopharmacology 22, 566-580 (2000) (Pubitemid 30219401)
31. Anisman H., Z. Merali: Anhedonic and anxiogenic effects of cytokine exposure. Adv Exp Med Biol 461, 199-233 (1999)
32. Hayley S., K. Brebner, S. Lacosta, Z. Merali, H. Anisman: Sensitization to the effects of tumor necrosis factor-alpha: neuroendocrine, central monoamine, and behavioral variations. J Neurosci 19, 5654-5665 (1999) (Pubitemid 29300227)
33. Hayley S., P. Wall, H. Anisman: Sensitization to the neuroendocrine, central monoamine and behavioural effects of murine tumor necrosis factor-alpha: peripheral and central mechanisms. Eur J Neurosci 15, 1061-1076 (2002) (Pubitemid 35463640)
34. Day H. E., E. J. Curran, S. J. Watson, Jr., H. Akil: Distinct neurochemical populations in the rat central nucleus of the amygdala and bed nucleus of the stria terminalis: evidence for their selective activation by interleukin-1beta. J Comp Neurol 413, 113-128 (1999) (Pubitemid 29409755)
35. Linthorst A. C., C. Flachskamm, P. Muller-Preuss, F. Holsboer, J. M. Reul: Effect of bacterial endotoxin and interleukin-1 beta on hippocampal serotonergic neurotransmission, behavioral activity, and free corticosterone levels: an in vivo microdialysis study. J Neurosci 15, 2920-2934 (1995)
36. Merali Z., S. Lacosta, H. Anisman: Effects of interleukin-1beta and mild stress on alterations of norepinephrine, dopamine and serotonin neurotransmission: a regional microdialysis study. Brain Res 761, 225-235 (1997) (Pubitemid 27305981)
37. Shintani F., S. Kanba, T. Nakaki, M. Nibuya, N. Kinoshita, E. Suzuki, G. Yagi, R. Kato, M. Asai: Interleukin-1 beta augments release of norepinephrine, dopamine, and serotonin in the rat anterior hypothalamus. J Neurosci 13, 3574-3581 (1993) (Pubitemid 23241191)
38. Song C., Z. Merali, H. Anisman: Variations of nucleus accumbens dopamine and serotonin following systemic interleukin-1, interleukin-2 or interleukin-6 treatment. Neuroscience 88, 823-836 (1999) (Pubitemid 28518260)
39. Zhang J., L. Terreni, M. G. De Simoni, A. J. Dunn: Peripheral interleukin-6 administration increases extracellular concentrations of serotonin and the evoked release of serotonin in the rat striatum. Neurochem Int 38, 303-308 (2001) (Pubitemid 32012990)
40. Schaefer M., M. Schwaiger, M. Pich, K. Lieb, A. Heinz: Neurotransmitter changes by interferon-alpha and therapeutic implications. Pharmacopsychiatry 36 Suppl 3, S203-206 (2003) (Pubitemid 38085138)
41. Anisman H., J. Gibb, S. Hayley: Influence of continuous infusion of interleukin-1beta on depressionrelated processes in mice: corticosterone, circulating cytokines, brain monoamines, and cytokine mRNA expression. Psychopharmacology (Berl) 199, 231-244 (2008)
42. Anisman H., M. O. Poulter, R. Gandhi, Z. Merali, S. Hayley: Interferon-alpha effects are exaggerated when administered on a psychosocial stressor backdrop: cytokine, corticosterone and brain monoamine variations. J Neuroimmunol 186, 45-53 (2007) (Pubitemid 46770860)
43. Cassidy E. M., D. Manning, S. Byrne, E. Bolger, F. Murray, N. Sharifi, E. Wallace, M. Keogan, V. O'Keane: Acute effects of low-dose interferon-alpha on serum cortisol and plasma interleukin-6. J Psychopharmacol 16, 230-234 (2002) (Pubitemid 34983078)
44. Shimizu H., K. Ohtani, N. Sato, T. Nagamine, M. Mori: Increase in serum interleukin-6, plasma ACTH and serum cortisol levels after systemic interferon-alpha administration. Endocr J 42, 551-556 (1995)
45. Gisslinger H., T. Svoboda, M. Clodi, B. Gilly, H. Ludwig, L. Havelec, A. Luger: Interferon-alpha stimulates the hypothalamic-pituitary-adrenal axis in vivo and in vitro. Neuroendocrinology 57, 489-495 (1993) (Pubitemid 23170154)
46. Kitagami T., K. Yamada, H. Miura, R. Hashimoto, T. Nabeshima, T. Ohta: Mechanism of systemically injected interferon-alpha impeding monoamine biosynthesis in rats: role of nitric oxide as a signal crossing the blood-brain barrier. Brain Res 978, 104-114 (2003) (Pubitemid 36780963)
47. Yokoyama M., E. Suzuki, T. Sato, S. Maruta, K. Inada, S. Watanabe, H. Miyaoka: Effects of intraperitoneal administration of IFN-alpha for one, four, and fourteen days on amino acid levels in various rat brain regions. J Interferon Cytokine Res 25, 187-191 (2005) (Pubitemid 40525305)
48. Raber J., G. F. Koob, F. E. Bloom: Interferon-alpha and transforming growth factor-beta 1 regulate corticotropinreleasing factor release from the amygdala: comparison with the hypothalamic response. Neurochem Int 30, 455-463 (1997) (Pubitemid 27136027)
49. Hori T., T. Katafuchi, S. Take, N. Shimizu: Neuroimmunomodulatory actions of hypothalamic interferon-alpha. Neuroimmunomodulation 5, 172-177 (1998)
50. De La Garza R., 2nd, G. M. Asnis: The non-steroidal anti-inflammatory drug diclofenac sodium attenuates IFN-alpha induced alterations to monoamine turnover in prefrontal cortex and hippocampus. Brain Res 977, 70-79 (2003) (Pubitemid 36638695)
51. Morikawa O., N. Sakai, H. Obara, N. Saito: Effects of interferon-alpha, interferon-gamma and cAMP on the transcriptional regulation of the serotonin transporter. Eur J Pharmacol 349, 317-324 (1998) (Pubitemid 28277103)
52. Yang W., Q. Wang, S. J. Kanes, J. M. Murray, K. Nishikura: Altered RNA editing of serotonin 5-HT2C receptor induced by interferon: implications for depression associated with cytokine therapy. Brain Res Mol Brain Res 124, 70-78 (2004) (Pubitemid 38496275)
53. Merali Z., T. Bedard, N. Andrews, B. Davis, A. T. McKnight, M. I. Gonzalez, M. Pritchard, P. Kent, H. Anisman: Bombesin receptors as a novel anti-anxiety therapeutic target: BB1 receptor actions on anxiety through alterations of serotonin activity. J Neurosci 26, 10387-10396 (2006) (Pubitemid 44564589)
54. Gurevich I., H. Tamir, V. Arango, A. J. Dwork, J. J. Mann, C. Schmauss: Altered editing of serotonin 2C receptor pre-mRNA in the prefrontal cortex of depressed suicide victims. Neuron 34, 349-356 (2002) (Pubitemid 34465494)
55. Schmauss C.: Serotonin 2C receptors: suicide, serotonin, and runaway RNA editing. Neuroscientist 9, 237-242 (2003) (Pubitemid 36899112)
56. Menkes D. B., J. A. MacDonald: Interferons, serotonin and neurotoxicity. Psychol Med 30, 259-268 (2000) (Pubitemid 30245790)
57. Capuron L., J. F. Gumnick, D. L. Musselman, D. H. Lawson, A. Reemsnyder, C. B. Nemeroff, A. H. Miller: Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology 26, 643-652 (2002) (Pubitemid 34260983)
58. Wichers M. C., G. H. Koek, G. Robaeys, A. J. Praamstra, M. Maes: Early increase in vegetative symptoms predicts IFN-alpha-induced cognitive-depressive changes. Psychol Med 35, 433-441 (2005) (Pubitemid 40372481)
59. Wichers M. C., M. Maes: The role of indoleamine 2, 3-dioxygenase (IDO) in the pathophysiology of interferonalpha-induced depression. J Psychiatry Neurosci 29, 11-17 (2004) (Pubitemid 38570008)
60. Parsadaniantz S. M., A. Lebeau, P. Duval, B. Grimaldi, B. Terlain, B. Kerdelhue: Effects of the inhibition of cyclooxygenase 1 or 2 or 5-lipoxygenase on the activation of the hypothalamic-pituitary-adrenal axis induced by interleukin-1beta in the male Rat. J Neuroendocrinol 12, 766-773 (2000) (Pubitemid 30497103)
61. van der Meer M. J., C. G. Sweep, G. J. Pesman, F. J. Tilders, A. R. Hermus: Chronic stimulation of the hypothalamus-pituitary-adrenal axis in rats by interleukin 1beta: central and peripheral mechanisms. Cytokine 8, 910-919 (1996) (Pubitemid 27091192)
62. Shuto H., Y. Kataoka, T. Horikawa, N. Fujihara, R. Oishi: Repeated interferon-alpha administration inhibits dopaminergic neural activity in the mouse brain. Brain Res 747, 348-351 (1997) (Pubitemid 27077413)
63. Abe S., T. Hori, T. Suzuki, A. Baba, H. Shiraishi, T. Yamamoto: Effects of chronic administration of interferon alpha A/D on serotonergic receptors in rat brain. Neurochem Res 24, 359-363 (1999) (Pubitemid 29072044)
64. De La Garza R., 2nd, G. M. Asnis, E. Pedrosa, C. Stearns, A. L. Migdal, J. F. Reinus, R. Paladugu, S. Vemulapalli: Recombinant human interferon-alpha does not alter reward behavior, or neuroimmune and neuroendocrine activation in rats. Prog Neuropsychopharmacol Biol Psychiatry 29, 781-792 (2005) (Pubitemid 40897796)
65. Bluthe R. M., V. Walter, P. Parnet, S. Laye, J. Lestage, D. Verrier, S. Poole, B. E. Stenning, K. W. Kelley, R. Dantzer: Lipopolysaccharide induces sickness behaviour in rats by a vagal mediated mechanism. C R Acad Sci III 317, 499-503 (1994) (Pubitemid 24220250)
66. Zhou D., N. Shanks, S. E. Riechman, R. Liang, A. W. Kusnecov, B. S. Rabin: Interleukin 6 modulates interleukin-1-and stress-induced activation of the hypothalamic-pituitary-adrenal axis in male rats. Neuroendocrinology 63, 227-236 (1996) (Pubitemid 26070809)
67. Van der Meer M. J., C. G. Sweep, G. J. Pesman, G. F. Borm, A. R. Hermus: Synergism between IL-1 beta and TNF-alpha on the activity of the pituitary-adrenal axis and on food intake of rats. Am J Physiol 268, E551-557 (1995)
68. Gandhi R., S. Hayley, J. Gibb, Z. Merali, H. Anisman: Influence of poly I: C on sickness behaviors, plasma cytokines, corticosterone and central monoamine activity: moderation by social stressors. Brain Behav Immun 21, 477-489 (2007) (Pubitemid 46528681)
69. Gibb J., S. Hayley, R. Gandhi, M. O. Poulter, H. Anisman: Synergistic and additive actions of a psychosocial stressor and endotoxin challenge: Circulating and brain cytokines, plasma corticosterone and behavioral changes in mice. Brain Behav Immun 22, 573-589 (2008)
70. Quan N., R. Avitsur, J. L. Stark, L. He, W. Lai, F. Dhabhar, J. F. Sheridan: Molecular mechanisms of glucocorticoid resistance in splenocytes of socially stressed male mice. J Neuroimmunol 137, 51-58 (2003) (Pubitemid 36351565)
71. Anisman H., Z. Merali, S. Hayley: Sensitization associated with stressors and cytokine treatments. Brain Behav Immun 17, 86-93 (2003) (Pubitemid 36369417)
72. Hayley S., S. Lacosta, Z. Merali, N. van Rooijen, H. Anisman: Central monoamine and plasma corticosterone changes induced by a bacterial endotoxin: sensitization and cross-sensitization effects. Eur J Neurosci 13, 1155-1165 (2001) (Pubitemid 32275753)
73. Schmidt E. D., A. W. Janszen, F. G. Wouterlood, F. J. Tilders: Interleukin-1-induced long-lasting changes in hypothalamic corticotropin- releasing hormone (CRH) - neurons and hyperresponsiveness of the hypothalamuspituitary-adrenal axis. J Neurosci 15, 7417-7426 (1995)
74. Johnson J. D., K. A. O'Connor, T. Deak, M. Stark, L. R. Watkins, S. F. Maier: Prior stressor exposure sensitizes LPS-induced cytokine production. Brain Behav Immun 16, 461-476 (2002) (Pubitemid 35346208)
75. Johnson J. D., K. A. O'Connor, M. K. Hansen, L. R. Watkins, S. F. Maier: Effects of prior stress on LPS-induced cytokine and sickness responses. Am J Physiol Regul Integr Comp Physiol 284, R422-432 (2003) (Pubitemid 36120159)
76. Johnson J. D., K. A. O'Connor, L. R. Watkins, S. F. Maier: The role of IL-1beta in stress-induced sensitization of pro-inflammatory cytokine and corticosterone responses. Neuroscience 127, 569-577 (2004) (Pubitemid 38993161)
77. Tilders F. J., E. D. Schmidt: Cross-sensitization between immune and non-immune stressors. A role in the etiology of depression? Adv Exp Med Biol 461, 179-197 (1999)
78. Shanks N., R. J. Windle, P. A. Perks, M. S. Harbuz, D. S. Jessop, C. D. Ingram, S. L. Lightman: Early-life exposure to endotoxin alters hypothalamic-pituitaryadrenal function and predisposition to inflammation. Proc Natl Acad Sci U S A 97, 5645-5650 (2000) (Pubitemid 30313772)
79. Weaver I. C., N. Cervoni, F. A. Champagne, A. C. D'Alessio, S. Sharma, J. R. Seckl, S. Dymov, M. Szyf, M. J. Meaney: Epigenetic programming by maternal behavior. Nat Neurosci 7, 847-854 (2004) (Pubitemid 38989508)
80. Yirmiya R., Y. Pollak, M. Morag, A. Reichenberg, O. Barak, R. Avitsur, Y. Shavit, H. Ovadia, J. Weidenfeld, A. Morag, M. E. Newman, T. Pollmacher: Illness, cytokines, and depression. Ann N Y Acad Sci 917, 478-487 (2000)
81. Dantzer R.: Cytokine-induced sickness behavior: mechanisms and implications. Ann N Y Acad Sci 933, 222-234 (2001) (Pubitemid 32386037)
82. Kusnecov A. W., R. Liang, G. Shurin: T-lymphocyte activation increases hypothalamic and amygdaloid expression of CRH mRNA and emotional reactivity to novelty. J Neurosci 19, 4533-4543 (1999) (Pubitemid 29241103)
83. Cohn D. W., L. C. de Sa-Rocha: Differential effects of lipopolysaccharide in the social behavior of dominant and submissive mice. Physiol Behav 87, 932-937 (2006)
84. Quan N., M. Herkenham: Connecting cytokines and brain: a review of current issues. Histol Histopathol 17, 273-288 (2002) (Pubitemid 34116430)
85. Bluthe R. M., S. Laye, B. Michaud, C. Combe, R. Dantzer, P. Parnet: Role of interleukin-1beta and tumour necrosis factor-alpha in lipopolysaccharide- induced sickness behaviour: a study with interleukin-1 type I receptor-deficient mice. Eur J Neurosci 12, 4447-4456 (2000) (Pubitemid 32037853)
86. Bluthe R. M., R. Dantzer, K. W. Kelley: Effects of interleukin-1 receptor antagonist on the behavioral effects of lipopolysaccharide in rat. Brain Res 573, 318-320 (1992)
87. Fortier M. E., S. Kent, H. Ashdown, S. Poole, P. Boksa, G. N. Luheshi: The viral mimic, polyinosinic: polycytidylic acid, induces fever in rats via an interleukin-1-dependent mechanism. Am J Physiol Regul Integr Comp Physiol 287, R759-766 (2004) (Pubitemid 39280460)
88. Fantuzzi G., H. Zheng, R. Faggioni, F. Benigni, P. Ghezzi, J. D. Sipe, A. R. Shaw, C. A. Dinarello: Effect of endotoxin in IL-1 beta-deficient mice. J Immunol 157, 291-296 (1996) (Pubitemid 26190560)
89. Goshen I., T. Kreisel, H. Ounallah-Saad, P. Renbaum, Y. Zalzstein, T. Ben-Hur, E. Levy-Lahad, R. Yirmiya: A dual role for interleukin-1 in hippocampal-dependent memory processes. Psychoneuroendocrinology 32, 1106-1115 (2007) (Pubitemid 350086829)
90. Hayley S., O. Kelly, H. Anisman: Corticosterone changes in response to stressors, acute and protracted actions of tumor necrosis factor-alpha, and lipopolysaccharide treatments in mice lacking the tumor necrosis factor-alpha p55 receptor gene. Neuroimmunomodulation 11, 241-246 (2004) (Pubitemid 38916096)
91. Simen B. B., C. H. Duman, A. A. Simen, R. S. Duman: TNFalpha signaling in depression and anxiety: behavioral consequences of individual receptor targeting. Biol Psychiatry 59, 775-785 (2006)
92. Yamada K., R. Iida, Y. Miyamoto, K. Saito, K. Sekikawa, M. Seishima, T. Nabeshima: Neurobehavioral alterations in mice with a targeted deletion of the tumor necrosis factor-alpha gene: implications for emotional behavior. J Neuroimmunol 111, 131-138 (2000)
93. Kemna E., P. Pickkers, E. Nemeth, H. van der Hoeven, D. Swinkels: Time-course analysis of hepcidin, serum iron, and plasma cytokine levels in humans injected with LPS. Blood 106, 1864-1866 (2005) (Pubitemid 41208606)
94. Harden L. M., I. du Plessis, S. Poole, H. P. Laburn: Interleukin-6 and leptin mediate lipopolysaccharideinduced fever and sickness behavior. Physiol Behav 89, 146-155 (2006)
95. Cartmell T., S. Poole, A. V. Turnbull, N. J. Rothwell, G. N. Luheshi: Circulating interleukin-6 mediates the febrile response to localised inflammation in rats. J Physiol 526 Pt 3, 653-661 (2000) (Pubitemid 30654768)
96. Lenczowski M. J., R. M. Bluthe, J. Roth, G. S. Rees, D. A. Rushforth, A. M. van Dam, F. J. Tilders, R. Dantzer, N. J. Rothwell, G. N. Luheshi: Central administration of rat IL-6 induces HPA activation and fever but not sickness behavior in rats. Am J Physiol 276, R652-658 (1999) (Pubitemid 29157493)
97. Wu T. H., C. H. Lin: IL-6 mediated alterations on immobile behavior of rats in the forced swim test via ERK1/2 activation in specific brain regions. Behav Brain Res (2008)
98. Bret-Dibat J. L., R. M. Bluthe, S. Kent, K. W. Kelley, R. Dantzer: Lipopolysaccharide and interleukin-1 depress food-motivated behavior in mice by a vagal-mediated mechanism. Brain Behav Immun 9, 242-246 (1995)
99. Kent S., J. L. Bret-Dibat, K. W. Kelley, R. Dantzer: Mechanisms of sickness-induced decreases in foodmotivated behavior. Neurosci Biobehav Rev 20, 171-175 (1996) (Pubitemid 126682126)
100. Bluthe R. M., R. Dantzer, K. W. Kelley: Central mediation of the effects of interleukin-1 on social exploration and body weight in mice. Psychoneuroendocrinology 22, 1-11 (1997) (Pubitemid 27191755)
101. Frenois F., M. Moreau, J. O'Connor, M. Lawson, C. Micon, J. Lestage, K. W. Kelley, R. Dantzer, N. Castanon: Lipopolysaccharide induces delayed FosB/DeltaFosB immunostaining within the mouse extended amygdala, hippocampus and hypothalamus, that parallel the expression of depressive-like behavior. Psychoneuroendocrinology 32, 516-531 (2007) (Pubitemid 46756007)
102. Moreau M., C. Andre, J. C. O'Connor, S. A. Dumich, J. A. Woods, K. W. Kelley, R. Dantzer, J. Lestage, N. Castanon: Inoculation of Bacillus Calmette-Guerin to mice induces an acute episode of sickness behavior followed by chronic depressive-like behavior. Brain Behav Immun 22, 1087-1095 (2008)
103. Borowski T., L. Kokkinidis, Z. Merali, H. Anisman: Lipopolysaccharide, central in vivo biogenic amine variations, and anhedonia. Neuroreport 9, 3797-3802 (1998) (Pubitemid 29189305)
104. Anisman H., L. Kokkinidis, T. Borowski, Z. Merali: Differential effects of interleukin (IL)-1beta, IL-2 and IL-6 on responding for rewarding lateral hypothalamic stimulation. Brain Res 779, 177-187 (1998) (Pubitemid 28039950)
105. Anisman H., L. Kokkinidis, Z. Merali: Further evidence for the depressive effects of cytokines: anhedonia and neurochemical changes. Brain Behav Immun 16, 544-556 (2002) (Pubitemid 35333734)
106. Merali Z., K. Brennan, P. Brau, H. Anisman: Dissociating anorexia and anhedonia elicited by interleukin-1beta: antidepressant and gender effects on responding for "free chow" and "earned" sucrose intake. Psychopharmacology (Berl) 165, 413-418 (2003) (Pubitemid 36223083)
107. Sammut S., I. Bethus, G. Goodall, R. Muscat: Antidepressant reversal of interferon-alpha-induced anhedonia. Physiol Behav 75, 765-772 (2002)
108. Sammut S., G. Goodall, R. Muscat: Acute interferonalpha administration modulates sucrose consumption in the rat. Psychoneuroendocrinology 26, 261-272 (2001) (Pubitemid 32144730)
109. Bluthe R. M., N. Castanon, F. Pousset, A. Bristow, C. Ball, J. Lestage, B. Michaud, K. W. Kelley, R. Dantzer: Central injection of IL-10 antagonizes the behavioural effects of lipopolysaccharide in rats. Psychoneuroendocrinology 24, 301-311 (1999) (Pubitemid 29118377)
110. Kelley K. W., R. M. Bluthe, R. Dantzer, J. H. Zhou, W. H. Shen, R. W. Johnson, S. R. Broussard: Cytokineinduced sickness behavior. Brain Behav Immun 17 Suppl 1, S112-118 (2003)
111. Wieczorek M., A. H. Swiergiel, H. Pournajafi-Nazarloo, A. J. Dunn: Physiological and behavioral responses to interleukin-1beta and LPS in vagotomized mice. Physiol Behav 85, 500-511 (2005) (Pubitemid 41020765)
112. Lacroix S., S. Rivest: Functional circuitry in the brain of immune-challenged rats: partial involvement of prostaglandins. J Comp Neurol 387, 307-324 (1997) (Pubitemid 27430353)
113. Sagar S. M., K. J. Price, N. W. Kasting, F. R. Sharp: Anatomic patterns of Fos immunostaining in rat brain following systemic endotoxin administration. Brain Res Bull 36, 381-392 (1995)
114. Aid S., R. Langenbach, F. Bosetti: Neuroinflammatory response to lipopolysaccharide is exacerbated in mice genetically deficient in cyclooxygenase-2. J Neuroinflammation 5, 17 (2008)
115. Morita I.: Distinct functions of COX-1 and COX-2. Prostaglandins Other Lipid Mediat 68-69, 165-175 (2002) (Pubitemid 35247394)
116. Dunn A. J., A. H. Swiergiel, H. Zhang, N. Quan: Reduced ingestion of sweetened milk induced by interleukin-1 and lipopolysaccharide is associated with induction of cyclooxygenase-2 in brain endothelia. Neuroimmunomodulation 13, 96-104 (2006) (Pubitemid 44804602)
117. Teeling J. L., L. M. Felton, R. M. Deacon, C. Cunningham, J. N. Rawlins, V. H. Perry: Sub-pyrogenic systemic inflammation impacts on brain and behavior, independent of cytokines. Brain Behav Immun 21, 836-850 (2007) (Pubitemid 47002211)
118. Dunn A. J.: Effects of the IL-1 receptor antagonist on the IL-1-and endotoxin-induced activation of the HPA axis and cerebral biogenic amines in mice. Neuroimmunomodulation 7, 36-45 (2000) (Pubitemid 30012577)
119. Swiergiel A. H., A. J. Dunn: Distinct roles for cyclooxygenases 1 and 2 in interleukin-1-induced behavioral changes. J Pharmacol Exp Ther 302, 1031-1036 (2002) (Pubitemid 34920223)
120. Maes M., S. Scharpe, E. Bosmans, M. Vandewoude, E. Suy, W. Uyttenbroeck, W. Cooreman, C. Vandervorst, J. Raus: Disturbances in acute phase plasma proteins during melancholia: additional evidence for the presence of an inflammatory process during that illness. Prog Neuropsychopharmacol Biol Psychiatry 16, 501-515 (1992)
121. Reichenberg A., R. Yirmiya, A. Schuld, T. Kraus, M. Haack, A. Morag, T. Pollmacher: Cytokine-associated emotional and cognitive disturbances in humans. Arch Gen Psychiatry 58, 445-452 (2001) (Pubitemid 32411324)
122. Alesci S., P. E. Martinez, S. Kelkar, I. Ilias, D. S. Ronsaville, S. J. Listwak, A. R. Ayala, J. Licinio, H. K. Gold, M. A. Kling, G. P. Chrousos, P. W. Gold: Major depression is associated with significant diurnal elevations in plasma interleukin-6 levels, a shift of its circadian rhythm, and loss of physiological complexity in its secretion: clinical implications. J Clin Endocrinol Metab 90, 2522-2530 (2005) (Pubitemid 40686286)
123. Bremmer M. A., A. T. Beekman, D. J. Deeg, B. W. Penninx, M. G. Dik, C. E. Hack, W. J. Hoogendijk: Inflammatory markers in late-life depression: results from a population-based study. J Affect Disord 106, 249-255 (2008)
124. Himmerich H., S. Fulda, J. Linseisen, H. Seiler, G. Wolfram, S. Himmerich, K. Gedrich, S. Kloiber, S. Lucae, M. Ising, M. Uhr, F. Holsboer, T. Pollmacher: Depression, comorbidities and the TNF-alpha system. Eur Psychiatry 23, 421-429 (2008)
125. Humphreys D., L. Schlesinger, M. Lopez, A. V. Araya: Interleukin-6 production and deregulation of the hypothalamic-pituitary-adrenal axis in patients with major depressive disorders. Endocrine 30, 371-376 (2006) (Pubitemid 47010974)
126. Kim Y. K., K. S. Na, K. H. Shin, H. Y. Jung, S. H. Choi, J. B. Kim: Cytokine imbalance in the pathophysiology of major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 31, 1044-1053 (2007)
127. Lanquillon S., J. C. Krieg, U. Bening-Abu-Shach, H. Vedder: Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacology 22, 370-379 (2000) (Pubitemid 30105765)
128. Mikova O., R. Yakimova, E. Bosmans, G. Kenis, M. Maes: Increased serum tumor necrosis factor alpha concentrations in major depression and multiple sclerosis. Eur Neuropsychopharmacol 11, 203-208 (2001) (Pubitemid 32611587)
129. Sutcigil L., C. Oktenli, U. Musabak, A. Bozkurt, A. Cansever, O. Uzun, S. Y. Sanisoglu, Z. Yesilova, N. Ozmenler, A. Ozsahin, A. Sengul: Pro-and antiinflammatory cytokine balance in major depression: effect of sertraline therapy. Clin Dev Immunol 2007, 76396 (2007)
130. Yang K., G. Xie, Z. Zhang, C. Wang, W. Li, W. Zhou, Y. Tang: Levels of serum interleukin (IL)-6, IL-1beta, tumour necrosis factor-alpha and leptin and their correlation in depression. Aust N Z J Psychiatry 41, 266-273 (2007) (Pubitemid 46705742)
131. Leo R., G. Di Lorenzo, M. Tesauro, C. Razzini, G. B. Forleo, G. Chiricolo, C. Cola, M. Zanasi, A. Troisi, A. Siracusano, R. Lauro, F. Romeo: Association between enhanced soluble CD40 ligand and proinflammatory and prothrombotic states in major depressive disorder: pilot observations on the effects of selective serotonin reuptake inhibitor therapy. J Clin Psychiatry 67, 1760-1766 (2006) (Pubitemid 44955158)
132. Owen B. M., D. Eccleston, I. N. Ferrier, A. H. Young: Raised levels of plasma interleukin-1beta in major and postviral depression. Acta Psychiatr Scand 103, 226-228 (2001) (Pubitemid 32154355)
133. Maes M.: The immunoregulatory effects of antidepressants. Hum Psychopharmacol 16, 95-103 (2001) (Pubitemid 32219729)
134. Muller N., M. J. Schwarz, S. Dehning, A. Douhe, A. Cerovecki, B. Goldstein-Muller, I. Spellmann, G. Hetzel, K. Maino, N. Kleindienst, H. J. Moller, V. Arolt, M. Riedel: The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry 11, 680-684 (2006) (Pubitemid 43989814)
135. de Jong J. C., P. B. van den Berg, H. Tobi, L. T. de Jong-van den Berg: Combined use of SSRIs and NSAIDs increases the risk of gastrointestinal adverse effects. Br J Clin Pharmacol 55, 591-595 (2003) (Pubitemid 36783201)
136. Steiner J., H. Bielau, R. Brisch, P. Danos, O. Ullrich, C. Mawrin, H. G. Bernstein, B. Bogerts: Immunological aspects in the neurobiology of suicide: elevated microglial density in schizophrenia and depression is associated with suicide. J Psychiatr Res 42, 151-157 (2008) (Pubitemid 350061255)
137. Kim Y. K., S. W. Lee, S. H. Kim, S. H. Shim, S. W. Han, S. H. Choi, B. H. Lee: Differences in cytokines between non-suicidal patients and suicidal patients in major depression. Prog Neuropsychopharmacol Biol Psychiatry 32, 356-361 (2008)
138. Dierynck I., A. Bernard, H. Roels, M. De Ley: Potent inhibition of both human interferon-gamma production and biologic activity by the Clara cell protein CC16. Am J Respir Cell Mol Biol 12, 205-210 (1995)
139. Eller T., V. Vasar, J. Shlik, E. Maron: Proinflammatory cytokines and treatment response to escitalopram in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 32, 445-450 (2008) (Pubitemid 351178962)
140. O'Brien S. M., P. Scully, P. Fitzgerald, L. V. Scott, T. G. Dinan: Plasma cytokine profiles in depressed patients who fail to respond to selective serotonin reuptake inhibitor therapy. J Psychiatr Res 41, 326-331 (2007) (Pubitemid 44854992)
141. Huang T. L., C. T. Lee: T-helper 1/T-helper 2 cytokine imbalance and clinical phenotypes of acute-phase major depression. Psychiatry Clin Neurosci 61, 415-420 (2007)
142. Rothermundt M., V. Arolt, J. Fenker, H. Gutbrodt, M. Peters, H. Kirchner: Different immune patterns in melancholic and non-melancholic major depression. Eur Arch Psychiatry Clin Neurosci 251, 90-97 (2001) (Pubitemid 32488037)
143. Kaestner F., M. Hettich, M. Peters, W. Sibrowski, G. Hetzel, G. Ponath, V. Arolt, U. Cassens, M. Rothermundt: Different activation patterns of proinflammatory cytokines in melancholic and non-melancholic major depression are associated with HPA axis activity. J Affect Disord 87, 305-311 (2005) (Pubitemid 41039953)
144. Anisman H., A. V. Ravindran, J. Griffiths, Z. Merali: Interleukin-1 beta production in dysthymia before and after pharmacotherapy. Biol Psychiatry 46, 1649-1655 (1999) (Pubitemid 30001607)
145. Vaccarino V., B. D. Johnson, D. S. Sheps, S. E. Reis, S. F. Kelsey, V. Bittner, T. Rutledge, L. J. Shaw, G. Sopko, C. N. Bairey Merz: Depression, inflammation, and incident cardiovascular disease in women with suspected coronary ischemia: the National Heart, Lung, and Blood Institutesponsored WISE study. J Am Coll Cardiol 50, 2044-2050 (2007) (Pubitemid 350087570)
146. Elovainio M., L. Keltikangas-Jarvinen, L. Pulkki-Raback, M. Kivimaki, S. Puttonen, L. Viikari, L. Rasanen, K. Mansikkaniemi, J. Viikari, O. T. Raitakari: Depressive symptoms and C-reactive protein: the Cardiovascular Risk in Young Finns Study. Psychol Med 36, 797-805 (2006) (Pubitemid 43744773)
147. Danner M., S. V. Kasl, J. L. Abramson, V. Vaccarino: Association between depression and elevated C-reactive protein. Psychosom Med 65, 347-356 (2003) (Pubitemid 36628886)
148. Liukkonen T., S. Silvennoinen-Kassinen, J. Jokelainen, P. Rasanen, M. Leinonen, V. B. Meyer-Rochow, M. Timonen: The association between C-reactive protein levels and depression: Results from the northern Finland 1966 birth cohort study. Biol Psychiatry 60, 825-830 (2006) (Pubitemid 44550038)
149. Frasure-Smith N., F. Lesperance, M. R. Irwin, C. Sauve, J. Lesperance, P. Theroux: Depression, C-reactive protein and two-year major adverse cardiac events in men after acute coronary syndromes. Biol Psychiatry 62, 302-308 (2007) (Pubitemid 47444279)
150. Abraham J., C. Y. Campbell, A. Cheema, T. J. Gluckman, R. S. Blumenthal, P. Danyi: C-reactive protein in cardiovascular risk assessment: a review of the evidence. J Cardiometab Syndr 2, 119-123 (2007)
151. Katrinchak C., K. Fritz: Clinical implications of C-reactive protein as a predictor of vascular risk. J Am Acad Nurse Pract 19, 335-340 (2007)
152. Lowe G. D., P. M. Sweetnam, J. W. Yarnell, A. Rumley, C. Rumley, D. Bainton, Y. Ben-Shlomo: C-reactive protein, fibrin D-dimer, and risk of ischemic heart disease: the Caerphilly and Speedwell studies. Arterioscler Thromb Vasc Biol 24, 1957-1962 (2004) (Pubitemid 39350319)
153. Arbelaez J. J., A. A. Ariyo, R. M. Crum, L. P. Fried, D. E. Ford: Depressive symptoms, inflammation, and ischemic stroke in older adults: a prospective analysis in the cardiovascular health study. J Am Geriatr Soc 55, 1825-1830 (2007) (Pubitemid 350043768)
154. Whooley M. A., C. M. Caska, B. E. Hendrickson, M. A. Rourke, J. Ho, S. Ali: Depression and inflammation in patients with coronary heart disease: findings from the Heart and Soul Study. Biol Psychiatry 62, 314-320 (2007) (Pubitemid 47444281)
155. Guzman A., L. H. Tonelli, D. Roberts, J. W. Stiller, M. A. Jackson, J. J. Soriano, S. Yousufi, K. J. Rohan, H. Komarow, T. T. Postolache: Mood-worsening with highpollen-counts and seasonality: a preliminary report. J Affect Disord 101, 269-274 (2007) (Pubitemid 46879939)
156. Postolache T. T., J. W. Stiller, R. Herrell, M. A. Goldstein, S. S. Shreeram, R. Zebrak, C. M. Thrower, J. Volkov, M. J. No, I. Volkov, K. J. Rohan, J. Redditt, M. Parmar, F. Mohyuddin, C. Olsen, M. Moca, L. H. Tonelli, K. Merikangas, H. D. Komarow: Tree pollen peaks are associated with increased nonviolent suicide in women. Mol Psychiatry 10, 232-235 (2005) (Pubitemid 40432675)
157. Postolache T. T., M. Lapidus, E. R. Sander, P. Langenberg, R. G. Hamilton, J. J. Soriano, J. S. McDonald, N. Furst, J. Bai, D. A. Scrandis, J. A. Cabassa, J. W. Stiller, T. Balis, A. Guzman, A. Togias, L. H. Tonelli: Changes in allergy symptoms and depression scores are positively correlated in patients with recurrent mood disorders exposed to seasonal peaks in aeroallergens. ScientificWorldJournal 7, 1968-1977 (2007)
158. Postolache T. T., H. D. Komarow: Allergy, depression, and suicide. Directions in Psychiatry 25, 59-66 (2005)
159. Tonelli L. H., J. Stiller, D. Rujescu, I. Giegling, B. Schneider, K. Maurer, A. Schnabel, H. J. Moller, H. H. Chen, T. T. Postolache: Elevated cytokine expression in the orbitofrontal cortex of victims of suicide. Acta Psychiatr Scand 117, 198-206 (2008) (Pubitemid 351207982)
160. Loftis J. M., M. Huckans, S. Ruimy, D. J. Hinrichs, P. Hauser: Depressive symptoms in patients with chronic hepatitis C are correlated with elevated plasma levels of interleukin-1beta and tumor necrosis factor-alpha. Neurosci Lett 430, 264-268 (2008)
161. Dunn R. T., T. A. Kimbrell, T. A. Ketter, M. A. Frye, M. W. Willis, D. A. Luckenbaugh, R. M. Post: Principal components of the Beck Depression Inventory and regional cerebral metabolism in unipolar and bipolar depression. Biol Psychiatry 51, 387-399 (2002) (Pubitemid 34251176)
162. Carrieri P. B., V. Provitera, T. De Rosa, G. Tartaglia, F. Gorga, O. Perrella: Profile of cerebrospinal fluid and serum cytokines in patients with relapsing-remitting multiple sclerosis: a correlation with clinical activity. Immunopharmacol Immunotoxicol 20, 373-382 (1998) (Pubitemid 28432235)
163. Hautecoeur P., G. Forzy, P. Gallois, V. Demirbilek, O. Feugas: Variations of IL2, IL6, TNF alpha plasmatic levels in relapsing remitting multiple sclerosis. Acta Neurol Belg 97, 240-243 (1997) (Pubitemid 128523426)
164. Kahl K. G., N. Kruse, H. Faller, H. Weiss, P. Rieckmann: Expression of tumor necrosis factor-alpha and interferon-gamma mRNA in blood cells correlates with depression scores during an acute attack in patients with multiple sclerosis. Psychoneuroendocrinology 27, 671-681 (2002) (Pubitemid 34655718)
165. Monteyne P., C. J. Sindic: Data on cytokine mRNA expression in CSF and peripheral blood mononuclear cells from MS patients as detected by PCR. Mult Scler 4, 143-146 (1998) (Pubitemid 28410041)
166. Monteyne P., V. Van Laere, R. Marichal, C. J. Sindic: Cytokine mRNA expression in CSF and peripheral blood mononuclear cells in multiple sclerosis: detection by RT-PCR without in vitro stimulation. J Neuroimmunol 80, 137-142 (1997) (Pubitemid 28015333)
167. Pucak M. L., K. A. Carroll, D. A. Kerr, A. I. Kaplin: Neuropsychiatric manifestations of depression in multiple sclerosis: neuroinflammatory, neuroendocrine, and neurotrophic mechanisms in the pathogenesis of immunemediated depression. Dialogues Clin Neurosci 9, 125-139 (2007) (Pubitemid 47075461)
168. Musselman D. L., A. H. Miller, M. R. Porter, A. Manatunga, F. Gao, S. Penna, B. D. Pearce, J. Landry, S. Glover, J. S. McDaniel, C. B. Nemeroff: Higher than normal plasma interleukin-6 concentrations in cancer patients with depression: preliminary findings. Am J Psychiatry 158, 1252-1257 (2001) (Pubitemid 32717699)
169. Soygur H., O. Palaoglu, E. S. Akarsu, E. S. Cankurtaran, E. Ozalp, L. Turhan, I. H. Ayhan: Interleukin-6 levels and HPA axis activation in breast cancer patients with major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 31, 1242-1247 (2007) (Pubitemid 47081310)
170. Jacobson C. M., B. Rosenfeld, H. Pessin, W. Breitbart: Depression and IL-6 blood plasma concentrations in advanced cancer patients. Psychosomatics 49, 64-66 (2008)
171. Capuron L., A. Ravaud, P. J. Neveu, A. H. Miller, M. Maes, R. Dantzer: Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy. Mol Psychiatry 7, 468-473 (2002) (Pubitemid 34712898)
172. Friebe A., M. J. Schwarz, M. Schmid-Wendtner, M. Volkenandt, F. Schmidt, M. Horn, G. Janssen, M. Schaefer: Pretreatment levels of sTNF-R1 and sIL-6R are associated with a higher vulnerability for IFN-alpha-induced depressive symptoms in patients with malignant melanoma. J Immunother 30, 333-337 (2007) (Pubitemid 46586649)
173. Wichers M. C., G. Kenis, C. Leue, G. Koek, G. Robaeys, M. Maes: Baseline immune activation as a risk factor for the onset of depression during interferon-alpha treatment. Biol Psychiatry 60, 77-79 (2006)
174. Capuron L., G. Neurauter, D. L. Musselman, D. H. Lawson, C. B. Nemeroff, D. Fuchs, A. H. Miller: Interferonalpha-induced changes in tryptophan metabolism. relationship to depression and paroxetine treatment. Biol Psychiatry 54, 906-914 (2003) (Pubitemid 37311353)
175. Capuron L., C. L. Raison, D. L. Musselman, D. H. Lawson, C. B. Nemeroff, A. H. Miller: Association of exaggerated HPA axis response to the initial injection of interferon-alpha with development of depression during interferon-alpha therapy. Am J Psychiatry 160, 1342-1345 (2003) (Pubitemid 41070955)
176. Kraus M. R., O. Al-Taie, A. Schafer, M. Pfersdorff, K. P. Lesch, M. Scheurlen: Serotonin-1A receptor gene HTR1A variation predicts interferon-induced depression in chronic hepatitis C. Gastroenterology 132, 1279-1286 (2007) (Pubitemid 46627592)
177. Angelino A. F., G. J. Treisman: Evidence-informed assessment and treatment of depression in HCV and interferon-treated patients. Int Rev Psychiatry 17, 471-476 (2005) (Pubitemid 43086673)
178. Bonaccorso S., V. Marino, M. Biondi, F. Grimaldi, F. Ippoliti, M. Maes: Depression induced by treatment with interferon-alpha in patients affected by hepatitis C virus. J Affect Disord 72, 237-241 (2002) (Pubitemid 35351283)
179. Hunt C. M., J. A. Dominitz, B. P. Bute, B. Waters, U. Blasi, D. M. Williams: Effect of interferon-alpha treatment of chronic hepatitis C on health-related quality of life. Dig Dis Sci 42, 2482-2486 (1997) (Pubitemid 28103784)
180. Loftis J. M., P. Hauser: The phenomenology and treatment of interferon-induced depression. J Affect Disord 82, 175-190 (2004) (Pubitemid 39370819)
181. Valentine A. D., C. A. Meyers: Neurobehavioral effects of interferon therapy. Curr Psychiatry Rep 7, 391-395 (2005) (Pubitemid 41684187)
182. Malaguarnera M., A. Laurino, I. Di Fazio, G. Pistone, M. Castorina, N. Guccione, L. Rampello: Neuropsychiatric effects and type of IFN-alpha in chronic hepatitis C. J Interferon Cytokine Res 21, 273-278 (2001) (Pubitemid 32727425)
183. Krueger J. M., F. J. Obal, J. Fang, T. Kubota, P. Taishi: The role of cytokines in physiological sleep regulation. Ann N Y Acad Sci 933, 211-221 (2001) (Pubitemid 32386036)
184. Irwin M.: Effects of sleep and sleep loss on immunity and cytokines. Brain Behav Immun 16, 503-512 (2002) (Pubitemid 35333730)
185. Capuron L., P. Hauser, D. Hinze-Selch, A. H. Miller, P. J. Neveu: Treatment of cytokine-induced depression. Brain Behav Immun 16, 575-580 (2002) (Pubitemid 35333737)
186. Collier J., R. Chapman: Combination therapy with interferon-alpha and ribavirin for hepatitis C: practical treatment issues. BioDrugs 15, 225-238 (2001)
187. Kraus M. R., A. Schafer, K. Schottker, C. Keicher, B. Weissbrich, I. Hofbauer, M. Scheurlen: Therapy of interferon-induced depression in chronic hepatitis C with citalopram: a randomised, double-blind, placebo-controlled study. Gut 57, 531-536 (2008) (Pubitemid 351442539)
188. Bonaccorso S., A. Puzella, V. Marino, M. Pasquini, M. Biondi, M. Artini, C. Almerighi, M. Levrero, B. Egyed, E. Bosmans, H. Y. Meltzer, M. Maes: Immunotherapy with interferon-alpha in patients affected by chronic hepatitis C induces an intercorrelated stimulation of the cytokine network and an increase in depressive and anxiety symptoms. Psychiatry Res 105, 45-55 (2001) (Pubitemid 34015882)
189. Corssmit E. P., R. Heijligenberg, C. E. Hack, E. Endert, H. P. Sauerwein, J. A. Romijn: Effects of interferon-alpha (IFN-alpha) administration on leucocytes in healthy humans. Clin Exp Immunol 107, 359-363 (1997) (Pubitemid 27049265)
190. Wichers M. C., G. Kenis, G. H. Koek, G. Robaeys, N. A. Nicolson, M. Maes: Interferon-alpha-induced depressive symptoms are related to changes in the cytokine network but not to cortisol. J Psychosom Res 62, 207-214 (2007) (Pubitemid 46161588)
191. Schiepers O. J., M. C. Wichers, M. Maes: Cytokines and major depression. Prog Neuropsychopharmacol Biol Psychiatry 29, 201-217 (2005) (Pubitemid 40202906)
192. Wichers M., M. Maes: The psychoneuroimmunopathophysiology of cytokine-induced depression in humans. Int J Neuropsychopharmacol 5, 375-388 (2002)
193. Mohr D. C., D. E. Goodkin, W. Likosky, N. Gatto, K. A. Baumann, R. A. Rudick: Treatment of depression improves adherence to interferon beta-1b therapy for multiple sclerosis. Arch Neurol 54, 531-533 (1997) (Pubitemid 27204238)
194. Borras C., J. Rio, J. Porcel, M. Barrios, M. Tintore, X. Montalban: Emotional state of patients with relapsingremitting MS treated with interferon beta-1b. Neurology 52, 1636-1639 (1999) (Pubitemid 29220640)
195. Patten S. B., L. M. Metz: Interferon beta-1 a and depression in relapsing-remitting multiple sclerosis: an analysis of depression data from the PRISMS clinical trial. Mult Scler 7, 243-248 (2001) (Pubitemid 32780695)
196. Patten S. B., L. M. Metz: Interferon beta1a and depression in secondary progressive MS: data from the SPECTRIMS Trial. Neurology 59, 744-746 (2002)
197. Goeb J. L., C. Even, G. Nicolas, B. Gohier, F. Dubas, J. B. Garre: Psychiatric side effects of interferon-beta in multiple sclerosis. Eur Psychiatry 21, 186-193 (2006)
198. Kraus M. R., A. Schafer, H. Faller, H. Csef, M. Scheurlen: Psychiatric symptoms in patients with chronic hepatitis C receiving interferon alfa-2b therapy. J Clin Psychiatry 64, 708-714 (2003) (Pubitemid 36750150)
199. Dieperink E., M. Willenbring, S. B. Ho: Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: A review. Am J Psychiatry 157, 867-876 (2000) (Pubitemid 30412335)
200. Lieb K., M. A. Engelbrecht, O. Gut, B. L. Fiebich, J. Bauer, G. Janssen, M. Schaefer: Cognitive impairment in patients with chronic hepatitis treated with interferon alpha (IFNalpha): results from a prospective study. Eur Psychiatry 21, 204-210 (2006) (Pubitemid 44316600)
201. George J., S. Bleasdale, S. J. Singleton: Causes and prognosis of delirium in elderly patients admitted to a district general hospital. Age Ageing 26, 423-427 (1997) (Pubitemid 28014905)
202. Rudolph J. L., B. Ramlawi, G. A. Kuchel, J. E. McElhaney, D. Xie, F. W. Sellke, K. Khabbaz, S. E. Levkoff, E. R. Marcantonio: Chemokines are associated with delirium after cardiac surgery. J Gerontol A Biol Sci Med Sci 63, 184-189 (2008) (Pubitemid 351738450)
203. Adamis D., A. Treloar, F. C. Martin, N. Gregson, G. Hamilton, A. J. Macdonald: APOE and cytokines as biological markers for recovery of prevalent delirium in elderly medical inpatients. Int J Geriatr Psychiatry 22, 688-694 (2007) (Pubitemid 47180383)
204. Wilson K., C. Broadhurst, M. Diver, M. Jackson, P. Mottram: Plasma insulin growth factor-1 and incident delirium in older people. Int J Geriatr Psychiatry 20, 154-159 (2005) (Pubitemid 40277894)
205. Broadhurst C., K. Wilson: Immunology of delirium: new opportunities for treatment and research. Br J Psychiatry 179, 288-289 (2001) (Pubitemid 32996036)
206. Kudoh A., H. Takase, H. Katagai, T. Takazawa: Postoperative interleukin-6 and cortisol concentrations in elderly patients with postoperative confusion. Neuroimmunomodulation 12, 60-66 (2005) (Pubitemid 40528911)
207. Pfister D., M. Siegemund, S. Dell-Kuster, P. Smielewski, S. Ruegg, S. P. Strebel, S. C. Marsch, H. Pargger, L. A. Steiner: Cerebral perfusion in sepsis-associated delirium. Crit Care 12, R63 (2008)
208. Beloosesky Y., J. Grinblat, A. Pirotsky, A. Weiss, D. Hendel: Different C-reactive protein kinetics in postoperative hip-fractured geriatric patients with and without complications. Gerontology 50, 216-222 (2004) (Pubitemid 39140314)
209. Beloosesky Y., D. Hendel, A. Weiss, A. Hershkovitz, J. Grinblat, A. Pirotsky, V. Barak: Cytokines and C-reactive protein production in hip-fracture-operated elderly patients. J Gerontol A Biol Sci Med Sci 62, 420-426 (2007) (Pubitemid 47065711)
210. Rafnsson S. B., I. J. Deary, F. B. Smith, M. C. Whiteman, F. G. Fowkes: Cardiovascular diseases and decline in cognitive function in an elderly community population: the Edinburgh Artery Study. Psychosom Med 69, 425-434 (2007) (Pubitemid 46987885)
211. Schram M. T., S. M. Euser, A. J. de Craen, J. C. Witteman, M. Frolich, A. Hofman, J. Jolles, M. M. Breteler, R. G. Westendorp: Systemic markers of inflammation and cognitive decline in old age. J Am Geriatr Soc 55, 708-716 (2007) (Pubitemid 46668977)
212. Bermejo P., S. Martin-Aragon, J. Benedi, C. Susin, E. Felici, P. Gil, J. M. Ribera, A. M. Villar: Differences of peripheral inflammatory markers between mild cognitive impairment and Alzheimer's disease. Immunol Lett 117, 198-202 (2008)
213. Mustafa A., L. Lannfelt, L. Lilius, A. Islam, B. Winblad, A. Adem: Decreased plasma insulin-like growth factor-I level in familial Alzheimer's disease patients carrying the Swedish APP 670/671 mutation. Dement Geriatr Cogn Disord 10, 446-451 (1999) (Pubitemid 29512010)
214. Cazzullo C. L., E. Sacchetti, A. Galluzzo, A. Panariello, F. Colombo, A. Zagliani, M. Clerici: Cytokine profiles in drugnaive schizophrenic patients. Schizophr Res 47, 293-298 (2001) (Pubitemid 32244114)
215. Maes M., E. Bosmans, R. Ranjan, E. Vandoolaeghe, H. Y. Meltzer, M. De Ley, R. Berghmans, G. Stans, R. Desnyder: Lower plasma CC16, a natural anti-inflammatory protein, and increased plasma interleukin-1 receptor antagonist in schizophrenia: effects of antipsychotic drugs. Schizophr Res 21, 39-50 (1996) (Pubitemid 26291899)
216. Naudin J., C. Capo, B. Giusano, J. L. Mege, J. M. Azorin: A differential role for interleukin-6 and tumor necrosis factoralpha in schizophrenia? Schizophr Res 26, 227-233 (1997) (Pubitemid 27431788)
217. Naudin J., J. L. Mege, J. M. Azorin, D. Dassa: Elevated circulating levels of IL-6 in schizophrenia. Schizophr Res 20, 269-273 (1996) (Pubitemid 26232971)
218. Zhang X. Y., D. F. Zhou, P. Y. Zhang, G. Y. Wu, L. Y. Cao, Y. C. Shen: Elevated interleukin-2, interleukin-6 and interleukin-8 serum levels in neuroleptic-free schizophrenia: association with psychopathology. Schizophr Res 57, 247-258 (2002) (Pubitemid 35240027)
219. Erbagci A. B., H. Herken, O. Koyluoglu, N. Yilmaz, M. Tarakcioglu: Serum IL-1beta, sIL-2R, IL-6, IL-8 and TNF-alpha in schizophrenic patients, relation with symptomatology and responsiveness to risperidone treatment. Mediators Inflamm 10, 109-115 (2001) (Pubitemid 32735303)
220. Zhang X. Y., D. F. Zhou, L. Y. Cao, G. Y. Wu, Y. C. Shen: Cortisol and cytokines in chronic and treatmentresistant patients with schizophrenia: association with psychopathology and response to antipsychotics. Neuropsychopharmacology 30, 1532-1538 (2005) (Pubitemid 41153125)
221. Chen X., K. S. Kendler: Interleukin 3 and schizophrenia. Am J Psychiatry 165, 13-14 (2008) (Pubitemid 351704545)
222. Lencz T., T. V. Morgan, M. Athanasiou, B. Dain, C. R. Reed, J. M. Kane, R. Kucherlapati, A. K. Malhotra: Converging evidence for a pseudoautosomal cytokine receptor gene locus in schizophrenia. Mol Psychiatry 12, 572-580 (2007) (Pubitemid 46816774)
223. Neri S., D. Pulvirenti, G. Bertino: Psychiatric symptoms induced by antiviral therapy in chronic hepatitis C: comparison between interferon-alpha-2a and interferonalpha-2b. Clin Drug Investig 26, 655-662 (2006) (Pubitemid 44627849)
224. Quarantini L. C., S. C. Cruz, S. C. Batista-Neves, R. Parana, A. Miranda-Scippa, R. A. Bressan: Psychosis during peginterferon-alpha 2a and ribavirin therapy: case report. Braz J Infect Dis 10, 406-407 (2006) (Pubitemid 46585572)
225. Cazzullo C. L., E. Sacchetti, A. Galluzzo, A. Panariello, A. Adorni, M. Pegoraro, S. Bosis, F. Colombo, D. Trabattoni, A. Zagliani, M. Clerici: Cytokine profiles in schizophrenic patients treated with risperidone: a 3-month follow-up study. Prog Neuropsychopharmacol Biol Psychiatry 26, 33-39 (2002) (Pubitemid 34045143)
226. Zhang X. Y., D. F. Zhou, L. Y. Cao, P. Y. Zhang, G. Y. Wu, Y. C. Shen: Changes in serum interleukin-2, -6, and -8 levels before and during treatment with risperidone and haloperidol: relationship to outcome in schizophrenia. J Clin Psychiatry 65, 940-947 (2004)
227. Lin A., G. Kenis, S. Bignotti, G. J. Tura, R. De Jong, E. Bosmans, R. Pioli, C. Altamura, S. Scharpe, M. Maes: The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6. Schizophr Res 32, 9-15 (1998) (Pubitemid 28338119)
228. Maes M., L. Bocchio Chiavetto, S. Bignotti, G. Battisa Tura, R. Pioli, F. Boin, G. Kenis, E. Bosmans, R. de Jongh, A. Lin, G. Racagni, C. A. Altamura: Effects of atypical antipsychotics on the inflammatory response system in schizophrenic patients resistant to treatment with typical neuroleptics. Eur Neuropsychopharmacol 10, 119-124 (2000) (Pubitemid 30120041)
229. Maes M., L. Bocchio Chiavetto, S. Bignotti, G. J. Battisa Tura, R. Pioli, F. Boin, G. Kenis, E. Bosmans, R. de Jongh, C. A. Altamura: Increased serum interleukin-8 and interleukin-10 in schizophrenic patients resistant to treatment with neuroleptics and the stimulatory effects of clozapine on serum leukemia inhibitory factor receptor. Schizophr Res 54, 281-291 (2002) (Pubitemid 34304221)
230. Inglot A. D., J. Leszek, E. Piasecki, A. Sypula: Interferon responses in schizophrenia and major depressive disorders. Biol Psychiatry 35, 464-473 (1994) (Pubitemid 24122329)